The ETERNAL project has successfully kicked-off in Valencia, Spain. This new four-year EC Horizon Europe Research and Innovation Action will contribute to sustainable development of pharmaceutical manufacture, use and disposal, by using and promoting full life cycle approaches covering design, manufacture, usage, and disposal, assessing the environmental risks of not only active pharmaceutical ingredients and residues or metabolites, but other chemicals and by-products of the production process. In other words, safe and sustainable pharmaceutical lifecycles by design.
Asphalion experts André Mota and Oriol Penon attended the meeting. Asphalion will provide regulatory guidance to support understanding of the environmental exposure and ecotoxicity during pharmaceuticals development to ensure the solutions are commercially deployable in the future through a compliant by design approach according to applicable regulatory guidelines and technical standards. Due to Asphalion expertise in the regulatory field, Asphalion will also engage with policy makers, regulators and standards bodies to ensure a regulatory framework that enables green innovation.
You can read the complete press release here: ETERNAL PROJECT PRESS RELEASE
For further information:
This project has received funding from the European Union’s Horizon Europe Framework Programme (HORIZON) under grant agreement No 101057668.
